BACKGROUND: T-cell-depleted, haploidentical transplantations (haplos) are commonly offered to patients who have high-risk, acute leukemia in the absence of a human leukocyte antigen (HLA) full-matched donor. METHODS: To determine the effect of transplantation period, the authors divided 308 adults with de novo, acute leukemia who underwent T-cell-depleted haplo from 2005 to 2015 into 2 groups, according the year in which they underwent transplantation (2005-2011 [n 5 191] and 2012-2015 [n 5 117]). RESULTS: The median age was 41 years in patients who underwent transplantation before 2012 and 46 years in those who underwent transplantation after 2012 (P 5 .04). Most patients had acute myeloid leukemia (75% vs 69%; P 5 .26) and were in first complete remission (CR1) (55% vs 64%; P 5 .12) at the time of transplantation. The cumulative incidence of grade 2, 3, and 4 acute graft-versus-host disease (GvHD) and chronic GvHD were not different between the 2 groups (acute GvHD: 20% vs 22% cumulative incidence in patients who underwent haplo before and after 2012, respectively [P 5 .67]; chronic GvHD: 19% vs 11% cumulative incidence, respectively; P 5 .12]. The 2-year relapse incidence was 20%, the nonrelapse mortality (NRM) rate was 48%, and no difference was observed over time (21% vs 19% [P 5 .72] and 54% vs 38% [P 5 .11] for patients who underwent haplo before and after 2012, respectively). The main cause of NRM was infection. Haplo after 2012 (hazard ratio [HR], 0.57; P 5 .01), younger age (HR, 0.82; P 5 .02), and receipt of a reduced-intensity conditioning (RIC) regimen (HR, 0.53; P 5 .01) were independently associated with lower NRM. The 2-year overall survival rate was 36% and improved after 2012 (29% vs 47% before 2012; P 5 .02); and it was higher for patients who underwent transplantation in CR1 (41% vs 29%; P 5 .01). In multivariate analysis, haplo after 2012 (HR, 0.54; P 5 .003) and receipt of a RIC regimen (HR, 0.54; P 5 .005) were independently associated with better overall survival. Similarly, leukemia-free survival and GvHD-free/relapse-free survival (GRFS) improved over time: the leukemia-free survival rate was 31% (25% vs 43% in the groups who underwent transplantation before and after 2012, respectively; P 5 .05), and the GRFS rate was 24% (19% vs 34%, respectively; P 5 .09). In addition, leukemia-free survival and GRFS improved among patients who received a RIC regimen. CONCLUSIONS: The outcome of patients with acute leukemia who underwent T-cell-depleted haplo has improved over time. Cancer 2018;124:2142-
INTRODUCTION
Hematopoietic transplantation represents a curative procedure for adult patients with high-risk acute leukemia. In the absence of a human leukocyte antigen (HLA)-matched donor, haploidentical transplantation (haplo) is an attractive option for almost all patients in need of allogeneic transplantation. 1 Recent European Society of Blood and Marrow Transplantation (EBMT) survey indicated that the numbers of haplos performed in Europe continues to increase, with myeloid malignancies being the main indication. 2 The approach of T-cell depletion with megadose CD34-positive cells pioneered by the Perugia group was the first to enable the performance of hematopoietic transplantation from family haploidentical donors across a broad HLA barrier without severe, lethal graft-versus-host disease (GvHD). 3 Originally, a combination of donor bone marrow (BM) and granulocyte-colony-stimulating factor (GCSF)mobilized peripheral blood stem cells was used to increase the stem cell dose: a combination that produced from 7fold to 10-fold higher levels (megadoses) of hematopoietic progenitor cells than those produced by BM allografts alone. The T-cell-depleted megadose allograft was able to overcome the historical barriers to haplo (ie, graft failure and GvHD). However, nonrelapse mortality (NRM) still remained high, mainly because of the high incidence of severe infections resulting from delayed immune reconstitution in addition to the high relapse rate resulting from up to a 4-log reduction in the graft T-cell content and the very efficient tolerance induction, which is mandatory for securing engraftment of the T-cell-depleted graft across a broad HLA barrier. 4, 5 Since those initial reports, progress has been made in the optimization of both conditioning regimens and graft selection using immunomagnetic purification of CD34-positive cells from mobilized peripheral blood stem cells. 6 After the initial single-center experience, the EBMT reported that a large, multicenter series of 266 patients with acute leukemia who underwent T-cell-depleted haplo using the megadose approach produced similar results. In that series, leukemia-free survival (LFS) was better for patients who had acute myeloid leukemia and were in first complete remission (CR1) at the time of transplantation; however, relapse incidence (RI) and NRM also remained high for patients who were in remission. 7 It is worth noting that, since 2008, no other multicenter studies have been performed assessing the results of T-cell-depleted haplo for acute leukemia. To analyze possible improvements over time in T-cell-depleted haplo for patients with acute leukemia in Europe, we report this registry-based study on behalf of the Acute Leukemia Working Party of the EBMT.
MATERIALS AND METHODS

Study Design
We analyzed all consecutive adults (age >18 years) who had de novo, acute leukemia in CR1 or second CR (CR2) at the time of transplantation and underwent T-celldepleted haplo as their first allogeneic transplantation between 2005 and 2015 in EBMT centers, reported to the Project Manager Internet Server (ProMISe) database. The EBMT is a voluntary working group of more than 500 transplantation centers that are required to report all consecutive stem cell transplantations and follow-ups once a year. Audits are routinely performed to determine the accuracy of the data. In total 308 patients were reported from 66 transplantation centers. To analyze the effect of transplantation period on T-cell-depleted haplo outcomes, patients were analyzed in 2 separate groups according to the median year of transplantation (2005-2011 [n 5 191; 62%] or 2012-2015 [n 5 117; 38%]). All donors were HLA-mismatched for at least at 2 loci (8 of 10; HLA type A major histocompatibility complex class I cell-surface receptor [HLA-A], HLA-B, HLA-C, HLA class II Drelated b1 [HLA-DRB1], and HLA-DQB1).
All grafts consisted of T-cell-depleted peripheral blood stem cells. T-cell depletion was performed according to the policy of the transplantation center. The exclusion criterion was previous allogeneic transplantation. Most patients (n 5 242; 78.6%) did not receive GvHD prophylaxis other than T-cell depletion, 24 patients (7.8%) received mycophenolate mofetil alone (n 5 14 [7.3%] before 2012 and n 5 10 [8.5%] after 2012), and 18 patients (5.8%) received cyclosporine alone (n 5 17 [8.9%] before 2012 and n 5 1 [0.9%] after 2012).
The study was approved by the Acute Leukemia Working Party of the EBMT Institutional Review Board and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients or legal guardians provided written informed consent authorizing the use of the information for research purposes.
Definitions and Statistical Analysis
The primary endpoint was LFS. Secondary endpoints were neutrophil engraftment, acute GvHD (aGvHD) and chronic GvHD (cGvHD), RI, NRM, GvHD-free/ relapse-free survival (GRFS), and overall survival (OS). Refined GRFS 8 was defined as survival without the following events: grade 3 and 4 aGvHD, severe cGvHD, disease relapse, or death from any cause after haplo. LFS was calculated until the date of first relapse or death from any cause. Relapse was defined as disease recurrence after CR. NRM was defined as death from any cause other than relapse. Engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count >0.5 3 10 9 / L. aGvHD was graded according to the modified Seattle Glucksberg criteria, 9 and cGvHD was graded according to the revised Seattle criteria. 10 The risk stratification of acute leukemia at diagnosis was established according to the National Comprehensive Cancer Network guideline (version 1.2015; National Comprehensive Cancer Network, Fort Washington, PA).
A myeloablative conditioning regimen (MAC) was defined as a regimen containing either total body irradiation (TBI) with a dose >6 grays, or a total dose of oral busulfan >8 mg/kg, or a total dose of intravenous busulfan >6.4 mg/kg, or melphalan at doses >140 mg/m 2 . In addition, regimens containing 2 alkylating agents were considered as MAC. All other regimens were defined as reduced-intensity conditioning (RIC). 11 GRFS, LFS, and OS were estimated using the Kaplan-Meier method. Cumulative incidence (CI) functions were used to estimate aGvHD, cGvHD, RI, and NRM. Competing risks were death from RI, relapse from NRM, and relapse or death from aGvHD or cGvHD. Univariate analyses were conducted using the log-rank test for GRFS, OS, and LFS and the Gray test for CI.
For univariate analysis, comparisons were made using chi-square tests for categorical variables and Mann-Whitney tests for continuous variables. Multivariate analyses were performed using the Cox proportional-hazards model. 
RESULTS
Patient and Transplantation Characteristics
Details of patients and transplant characteristics are reported in Table 1 . Median follow-up calculated using reverse Kaplan-Meier method was 54 months (95% confidence interval, 40.7-67.9 months) and 16.2 months (95% confidence interval, 11.7-20.7 months) for patients who underwent transplantation between 2005 and 2011 and between 2012 and 2015, respectively (P < .001).
The median patient age was 41 years and 46 years in those who underwent transplantation before and after 2012, respectively (P 5 .04). The majority of patients received a T-cell-depleted haplo for acute myeloid leukemia (75% before 2012 vs 69% after 2012; P 5 .26), with no differences according to transplantation period. Disease status at haplo was CR1 in 55% and 64% of patients who underwent transplantation before and after 2012, respectively (P 5 .11), with no differences between the 2 groups. Patients who underwent transplantation before 2012 more frequently had a Karnofsky performance status <90% (19% vs 10%; P 5 .04).
The median CD34-positive dose was 8.4 3 10 6 /kg (range, 0.9-18.8 3 10 6 /kg) ( Table 1) . Two hundred thirtyfour patients (76%) received a MAC preparative regimen, and 72 patients (24%) received an RIC preparative regimen (P 5 .94) ( Table 1 ). Most patients received in vivo T-cell depletion using antithymocyte globulin (ATG) (n 5 138 [87%] before 2012 and n 5 80 [88%] after 2012, respectively; P 5 .9). Overall, of 146 patients who had information available, 88 received Thymoglobulin (Sanofi-Aventis, Paris, France) and 58 patients received Fresenius (Neovii-Biotech GmbH, Graefelfing, Germany) as type of ATG.
Engraftment and GvHD
The CI of neutrophil engraftment at 60 days was 93.6% (95% confidence interval, 90%-96%) in the whole population, and there was no difference according to transplantation period (93% before 2012 and 90% after 2012; P 5 .30). The overall the CI of grade 2 through 4 aGvHD was 18%, with no difference according to transplantation period (20% and 22% before and after 2012, respectively; P 5 .66). Before 2012, 22 patients (11.8%) developed grade 2 aGvHD, 7 (3.7%) developed grade 3 aGvHD, and 7 (3.7%) developed grade 4 aGvHD; whereas, after 2012, 10 (8.7%) patients developed grade 2 aGvHD, 15 (13%) developed grade 3 aGvHD, and 0 developed grade 4 aGvHD.
The CI of 2-year cGvHD was 17%, with no difference between groups (19% and 11% before and after 2012, respectively; P 5 .11). cGvHD was reported as extensive in 6 patients before 2012 and in 4 patients after 2012, with no differences over time (P 5 .52).
RI and NRM
The 2-year RI was 20%, with no difference before and after 2012 (21% vs 19%, respectively; P 5 .72) ( Table 2 , Fig. 1 ). In multivariate analysis (Table 3) , disease status (CR2 vs CR1) was the only factor associated with higher RI (HR, 2.05; 95% confidence interval, 1.09-3.84; P 5 .02).
NRM was 48%, being 54% versus 38%; P 5 .10, according to the transplant period ( Table 2 , Fig. 1 ). The main cause of NRM was infection responsible of 2-year death in 33% of patients before 2012 and in 25% of patients after 2012 (P 5 .32). T-cell-depleted haplo after 2012 (HR, 0.57; 95% confidence interval, 0.38-0.86; P 5 .008), younger age at haplo (HR, 0.82; 95% confidence interval, 0.63-0.98; P 5 .023), and receipt of an RIC regimen (HR, 0.53; 95% confidence interval, 0.32-0.88; P 5 .014) were independently associated with lower NRM (Table 3) .
OS, LFS, and GRFS
Overall, the 2-year OS, LFS, and GRFS rates were 36% (95% confidence interval, 29.3%-42%), 31% (95% confidence interval, 25.1%-37.4%), and 24% (95% Original Article confidence interval, 18.4%-29.5%), respectively. Results from T-cell-depleted haplo over time (before and after 2012) improved, with an OS rate of 29% versus 47% for OS, respectively (P 5 .02) ( Fig. 1) ; an LFS rate of 25% versus 43%, respectively, for LFS (P 5 .05) (Fig. 1) ; and an GRFS rate of 19% versus 34%, respectively (P 5 .09). According to disease status, 2-year OS, LFS and GRFS rates were higher for patients who underwent transplantation in CR1 versus those who underwent transplantation in CR2 (41% vs 29% [P 5 .006], 38% vs 22% [P < .001], and 30% vs 17% [P 5 .004]. respectively) ( Table 2) . Two-year OS, LFS, and GRFS rates also were higher for patients who underwent transplantation after receiving an RIC regimen (44% vs 26% [P 5 .043], 48% vs 31% [P 5 .018], and 40% vs 19% [P 5 .006], respectively) ( Table 2 ).
In multivariate analysis (Table 3) , T-cell-depleted transplantation after 2012 (HR, 0.58; 95% confidence interval, 0.41-0.84; P 5 .003), disease status (HR, 0.65; 95% confidence interval, 0.90-0.49; P 5 .008), and receipt of an RIC regimen (HR, 0.64; 95% confidence interval, 0.42-0.97; P 5 .034) were associated with higher LFS. Similarly, T-cell-depleted haplo after 2012 versus before 2012 was independently associated with better OS and GRFS (HR, 0.54 [95% confidence interval, 0.38-0.79; P 5 .003] vs HR, 0.56 [95% confidence interval, 0.39-0.79; P 5 .001], respectively) and RIC regimen (HR, 0.54 [95% confidence interval, 0.35-0.83; P 5 .005] vs HR, 0.59 [95% confidence interval, 0.38-0.90; P 5 .016], respectively). We also tested the center effect in all multivariate models, and no significant differences were observed according to the main outcomes.
DISCUSSION
In this multicenter, registry-based, retrospective study, we analyzed the clinical outcomes of allogeneic transplantation from T-cell-depleted haploidentical donors in a large series of adult patients with de novo acute leukemia (all of whom were in CR at the time of transplantation) who underwent transplantation between 2005 and 2015. It is noteworthy that we focused on an analysis of the effect of transplantation period (before or after 2012) on T-cell-depleted haplo outcomes.
Our study confirms that it is possible to achieve a high engraftment rate and low incidence of GvHD without any post-transplantation immunosuppressive treatment across a broad HLA barrier by infusing a large number of immune-selected, CD34-positive cells through ex-vivo T-cell depletion using the CliniMACS system (Miltenyi Biotec Inc, Auburn, CA). The incidence of grade 2 through 4 aGvHD and cGvHD in patients who underwent transplantation before or after 2012 is consistent with previous reports in this setting.
T-cell-depleted haplo results improved with time, including the NRM rate, which reached 54% in those who underwent haplo before 2012 and was reduced by 16% in those who underwent haplo after 2012. Factors that predicted for reduced NRM were younger age at transplantation and receipt of an RIC preparative regimen, in line with previous studies in which NRM was higher with MAC regimens. 12 Overall, the main cause of NRM was infection, which was responsible of 2-year mortality in 33% of patients who underwent haplo before 2012 and in 25% of those who underwent haplo after 2012. In the current study, in addition to ex-vivo T-cell depletion of the donor grafts, in-vivo depletion by ATG has been realized in the majority of patients. Even if the high incidence of infections with the use of ATG is well known, reflecting an influence on the recovery of lymphocyte subpopulations, 13 gaining more experience at the different centers and providing better supportive care (including better management of infectious complications) are some of the reasons that may have contributed to the reduction in NRM, as also reported in previous EBMT multicenter series of T-cell-depleted haplo 7 and in other types of transplantation. 14 Notably, in addition to reduced NRM, the rates of LFS, OS, and GRFS improved significantly in those who underwent haplo with RIC after 2012, without paying the price of a higher relapse rate that did not differ between RIC and MAC in our cohort of patients with leukemia who underwent transplantation in CR. This is in contrast to results reported in the T-cell-replete haplo setting. 15 Furthermore, this finding is of major interest, because the grafts in T-cell-depleted haplo are depleted from T-cells and lack a fast-donor T-cell recovery secondary to profound graft T-cell depletion, thus limiting the overall antileukemia potential of this transplantation modality compared with recently reported, alternative non-T-cell-deleted options. 16 Therefore, it is interesting to note that, despite the absence of myeloablative regimens to control leukemia burden, the incidence of relapse was not higher with RIC. It is conceivable that a broad HLA-mismatched triggered graft-versus-leukemic effect probably was responsible, 17 even if a stronger graft-versusleukemic effect has not been demonstrated in haplo compared with HLA-identical siblings. 18 In the majority of previous single-center studies 3-5 and in the EBMT multicenter survey, 7 patients who underwent T-cell-depleted haplo received an MAC regimen and had a similar RI of approximately 20%. A non-TBI-based, reduced-intensity regimen was reported in a small number of patients by Lacerda et al, 19 who performed T-cell-depleted haplo followed by pre-emptive donor lymphocyte infusion to prevent disease relapse. 19 Ciurea and collegaues 20 evaluated the feasibility of a combined fludarabine, melphalan, thiotepa, and ATG reduced-intensity conditioning regimen in 28 patients undergoing haplo; 78% of patients with acute myeloid leukemia/myelodysplastic syndrome in that trial were not in remission at the time of transplantation, and all of them achieved remission after haplo. Twelve patients (44%), all with active disease, relapsed after a median of 72 days post-transplantation. Overall, the 1-year OS rate was 29%. 20 In the current study, we observed that the most significant prognostic factor for prediction of relapse was disease status. Notably, in recent years, many studies have confirmed this correlation: the EBMT survey of T-celldepleted haplo in Europe published in 2008 7 reported that, for patients with acute myeloid leukemia who underwent transplantation in remission, the 2-year CI of relapse was 16% for those in CR1 and 23% for those in CR2. Furthermore, in line with our results, the 2-year rate LFS was 48% and 21% for patients with acute myeloid leukemia who underwent T-cell-depleted haplo in CR1 and CR2, respectively.
In multivariate analysis, no clear effect of treatment center was documented despite the unbalanced distribution haplo procedures. The center effect was demonstrated previously by our group in the T-cell-depleted setting among both children 21 and adults 7 and usually was attributed to different management of post-transplant complications, life-threating infections, and relapse at each center. Our current results indicate no center effect, most probably indicating an improvement across the board with increased experience, not only for few specialized centers but also for small transplantation centers that perform selected, CD34-positive haplo.
Our study has some limitations, because it was a retrospective, registry-based study encompassing various conditioning regimens and partially lacking data on disease risk features, killer-cell immunoglobulin-like receptor analysis of patients and donors, as well as details of the specific management of complications, including relapses and post-transplantation therapy. However, in the current literature, our registry-based survey produced consistent results in the largest number of patients to date who underwent T-cell-depleted haplo.
In conclusion, the outcomes of patients who undergo T-cell-depleted haplo have improved over time in Europe. This observation is important especially because, currently, for most haplos in Europe and United States, the unmanipulated (T-replete) approach is used, 1, 2 whereas the T-cell-depleted haplo is not just an alternative option but provides a perfect platform for adoptive cellular therapy. With the emerging cell-based strategies [22] [23] [24] aimed at improving post-transplantation immune recovery, a further reduction in infectious complications can be expected and will translate into even better outcomes. T-cell-depleted haplo remains a valid option, especially for patients in CR, and this strategy may be considered for in the donor-selection treatment algorithm for patients who lack a matched donor. 
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